Evolent Health (EVH)

• Market cap: $1.11B
• 1 day: 1.90%
• 5 days: 3.99%
• 1 month: 10.03%
• 3 months: -16.01%
• 6 months: -64.33%
• Year to date: -16.01%
• 1 year: -69.78%
• 5 years: 101.04%
• 10 years: -48.83%
• Sector: Industrials
• Industry: Management Services

About: Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Employees: 4,700

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

58% more call options, than puts

Call options by funds: $20.2M | Put options by funds: $12.8M

29% more repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 69

8% less funds holding

Funds holding: 260 [Q3] → 238 (-22) [Q4]

8.7% less ownership

Funds ownership: 113.72% [Q3] → 105.02% (-8.7%) [Q4]

17% less first-time investments, than exits

New positions opened: 58 | Existing positions closed: 70

63% less capital invested

Capital invested by funds: $3.73B [Q3] → $1.38B (-$2.36B) [Q4]

71% less funds holding in top 10

Funds holding in top 10: 7 [Q3] → 2 (-5) [Q4]

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 24% upside
• Avg. target: $14.77 53% upside
• High target: $18 87% upside

13 analyst ratings

• positive: 12 92%
• neutral: 1 8%
• negative: 0 0%

JP Morgan Anne Samuel 51% 1-year accuracy 18 / 35 met price target	24% upside $12	Overweight Maintained	10 Mar 2025
Citizens Capital Markets Constantine Davides 30% 1-year accuracy 10 / 33 met price target	24% upside $12	Market Outperform Maintained	24 Feb 2025
Piper Sandler Jessica Tassan 38% 1-year accuracy 9 / 24 met price target	66% upside $16	Overweight Reiterated	21 Feb 2025
Needham Ryan MacDonald 40% 1-year accuracy 34 / 84 met price target	55% upside $15	Buy Reiterated	21 Feb 2025
JMP Securities Constantine Davides 30% 1-year accuracy 10 / 33 met price target	24% upside $12	Market Outperform Reiterated	14 Feb 2025